COVID-19 Infection in Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitor in Makassar, Indonesia: A Six-Case Report and Literature Review
Keywords:
Chronic Myeloid Leukemia, Tyrosine Kinase Inhibitor, COVID-19, Case ReportAbstract
Management of chronic myeloid leukemia (CML) in patients who are infected with COVID-19 is a challenging task due to disease-related or treatment-related factors that place such patients at a higher risk of complications. However, a low-infectivity-rate mechanism has been proposed by some researchers. In CML patients with COVID-19 infection, the most important treatment-related factor involves tyrosine kinase inhibitors (TKIs). In this case report, six patients with chronic-phase CML who experienced COVID-19 of mild–moderate severity all continued to receive TKI treatment for CML concurrently with COVID-19 treatment. All patients fully recovered. In the present study, we also review four other cases of COVID-19 infection in CML patients. Outcomes for TKI-treated CML patients who contract COVID-19 are influenced by many factors. Tyrosine kinase inhibitor therapy may benefit CML patients due to its antiviral effect, but the interaction between TKIs and drugs used for COVID-19 treatment requires careful monitoring. An individual approach is needed in every case.References
Eşkazan AE. Evolving treatment strategies in CML – moving from early and deep molecular responses to TKI discontinuation and treatment-free remission: is there a need for longer-term trial outcomes? Br J Clin Pharmacol. 2018;84(8):1635–8.
Hochhaus A, Baccarani M, Silver RT, et al. European Leukemia Net 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–84.
Silondae R, Harjianti T, Saleh S, et al. A Three-Years Survival Rates of Chronic Myeloid Leukemia Patients with Targeted Therapy. Indian J Public Heal Res Dev. 2020;11(1):1436–42.
Reksodiputro, ArryHarryanto, Atmakusuma, et al. Chronic Myeloid Leukemia in Indonesia. Jakarta: Dharmais Hospital National Cancer Centre. 2018.
Yigenoglu TN, Ata N, Altuntas F, et al. The outcome of COVID-19 in patients with hematological malignancy. J Med Virol. 2021;93(2):1099–104.
Breccia M, Abruzzese E, Bocchia M, et al. Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey. Leukemia. 2020;34(8):2260–1.
Nesr G, Saleem Z, Arami S. Outcome of COVID-19 in patients with chronic myeloid leukemia: A single centre UK experience. J Med Virol. 2022;94(4):1274–6.
Ibrahm RI, Chatzis GP, Korayem MA, et al. Management of chronic myeloid leukemia with sever covid 19: A case report. Open Access Maced J Med Sci. 2020;8(T1):304–8.
Yılmaz U, Pekmezci A, Gül Y, et al. COVID-19 in chronic-phase chronic myeloid leukemia patients: A single-center survey from Turkey. Turkish J Hematol. 2021;38(1):79–81.
Li W, Wang D, Guo J, et al. COVID-19 in persons with chronic myeloid leukaemia. Leukemia. 2020;34(7):1799–804.
Rea D, Mauro MJ, Cortes JE, et al. COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study. Blood. 2020;136(Supplement 1):46–7.
Radich JP, Kok CH, Chelysheva EY, et al. A Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income. Blood. 2022;140(Supplement 1):9617–9.
Kurniawan A, Lugito NPH, Baskoro BA, et al. Management of Cancer Patients during Coronavirus Disease 2019 Pandemic: A Literature Review. Indones J Cancer. 2020;14(2):69.
Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–7.
Coleman CM, Sisk JM, Mingo RM,et al. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion. J Virol. 2016;90(19):8924–33.
Sisk JM, Frieman MB, Machamer CE. Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors. J Gen Virol. 2018;99(5):619–30.
Galimberti S, Petrini M, Baratè C, et al. Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2. Front Oncol. 2020;10(September):1–9.
Hughes A, Yong ASM. Immune effector recovery in chronic myeloid leukemia and treatment-free remission. Front Immunol. 2017;8(April):1–12.
Jasielec JK, Larson RA. Dasatinib-related pulmonary toxicity mimicking an atypical infection. J Clin Oncol. 2016;34(6):e46–8.
Eskazan AE, Soysal T, Ongoren S, et al. Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy. Haematologica. 2011;28(3):2011.
Haguet H, Bouvy C, Delvigne AS, et al. The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study. Front Pharmacol. 2020;11(July):1–11.
Eskazan AE. Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic. Br J Clin Pharmacol. 2020;86(April):1790–2.
Zampino R, Mele F, Florio LL, et al. Liver injury in remdesivir-treated COVID-19 patients. Hepatol Int [Internet]. 2020;14(5):881–3. Available from: https://doi.org/10.1007/s12072-020-10077-3
Béchade D, Chakiba C, Desjardin M,et al. Hepatotoxicity of tyrosine kinase inhibitors: Mechanisms involved and practical implications. Bull Cancer [Internet]. 2018;105(3):290–8. Available from: http://dx.doi.org/10.1016/j.bulcan.2017.11.015
Backman JT, Filppula AM, Niemi M, et al. Role of Cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016;68(1):168–241.
Fenner KS, Troutman MD, Kempshall S, et al. Drug-drug interactions mediated through P-glycoprotein: Clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther. 2009;85(2):173–81.
Michael Mauro, Druker B, Radich J, et al. COVID-19 and CML: Frequently Asked Questions [Internet]. American Society of Hematology. 2021 [cited 2022 Apr 21]. Available from: https://www.hematology.org/covid-19/covid-19-and-cml
Rasyid H, Sangkereng A, Harjianti T, et al. Impact of age to ferritin and neutrophil- lymphocyte ratio as biomarkers for intensive care requirement and mortality risk in 19 patients in Makassar , Indonesia. Physiol Rep. 2021;9(10):1–10.
Zhang H, Han H, He T, et al. Clinical Characteristics and Outcomes of COVID-19 – Infected Cancer Patients : A Systematic Review and Meta-Analysis. J Natl Cancer Inst. 2021;113:371–80.
Sandoval M, Nguyen DT, Vahidy FS, et al. Risk factors for severity of COVID-19 in hospital patients age 18-29 years. PLoS One [Internet]. 2021;16(7 July):1–22. Available from: http://dx.doi.org/10.1371/journal.pone.0255544
Downloads
Published
How to Cite
Issue
Section
License
CopyrightThe authors who publish this journal agree to the following requirements:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)
The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.
